跳至主要内容
临床试验/JPRN-UMIN000002177
JPRN-UMIN000002177已完成4 期

Prospective randomized controlled trial Comparing Peg-IFN alpha-2a monotherapy versus Peg-IFN alpha-2a +ribavirin combination therapy after curative ablation for HCV-positive Hepatocellular Carcinoma - Comparing Peg-IFN alpha-2a(+RBV) for HCV-positive hepatocellular carcinoma patients after curative ablation.

Yokohama City University Medical Center Gastroenterological Center0 个研究点目标入组 95 人开始时间: 2009年7月10日最近更新:
适应症

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
95

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • Patient with 1.pregnant or lactating women and women who may be pregnant 2. a man who can not avoid conception during administration of ribavirin and until 6 month after the end ribavirin treatment 3. allergic to ribavirin or nucleoside analogues 4.hemoglobinopathy(thalassemia, sickle cell disease) 5.an uncontrollable heart trouble (myocardial infarction, heart failure, or arrhythmia) 6.an poorly controlled diabetes mellitus and hypertension 7. severe renal disease, Ccr <50ml/min 8. severe depression or psychosomatic disorders 9 .liver disease such as autoimmune hepatitis 10.clinical laboratory date does not meet selection criterion 11. drug allergy against interferon

研究者

发起方
Yokohama City University Medical Center Gastroenterological Center

相似试验